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OBJECTIVE— The International Diabetes Mellitus Practice Study is a 5-year survey docu-
menting changes in diabetes treatment practice in developing regions.
RESEARCH DESIGN AND METHODS— Logistic regression analysis was used to
identify factors for achieving A1C7% in 11,799 patients (1,898 type 1 diabetic and 9,901 type
2 diabetic) recruited by 937 physicians from 17 countries in Eastern Europe (n  3,519), Asia
(n  5,888), Latin America (n  2,116), and Africa (n  276).
RESULTS— Twenty-two percent of type 1 diabetic and 36% of type 2 diabetic patients never had
A1C measurements. In those with values for A1C, blood pressure, and LDL cholesterol, 7.5% of type
1 diabetic (n696) and 3.6% of type 2 diabetic (n3,896) patients attained all three recommended
targets (blood pressure 130/80 mmHg, LDL cholesterol 100 mg/dl, and A1C 7%). Self-
monitoring of blood glucose was the only predictor for achieving the A1C goal in type 1 diabetes
(odds ratios: Asia 2.24, Latin America 3.55, and Eastern Europe 2.42). In type 2 diabetes, short
disease duration (Asia 0.97, Latin America 0.97, and Eastern Europe 0.82) and treatment with few
oral glucose–lowering drugs (Asia 0.64, Latin America 0.76, and Eastern Europe 0.62) were predic-
tors. Other region-specific factors included lack of microvascular complications and old age in Latin
America and Asia; health insurance coverage and specialist care in Latin America; lack of obesity and
self-adjustment of insulin dosages in Asia; and training by a diabetes educator, self-monitoring of blood
glucose in patients who self-adjusted insulin, and lack of macrovascular complications in Eastern Europe.
CONCLUSIONS— In developing countries, factors pertinent to patients, doctors, and
health care systems all impact on glycemic control.
Diabetes Care 32:227–233, 2009
A lthough optimizing diabetes carereduces death and complicationrates (1–3), multiple barriers
hinder turning evidence into practice
(4,5). Most diabetic patients reside in de-
veloping countries (6) where standardized
data on quality of care is relatively scarce.
The International Diabetes Management
Practices Study (IDMPS) is an ongoing ob-
servational survey to collect, analyze, and
disseminate data in a standardized manner.
By documenting changes in practices over
time in a broad range of health care settings,
we aim to raise awareness and identify bar-
riers to quality diabetes care. Other objec-
tives include evaluation of clinical progress,
levels of compliance, attainment of treat-
ment targets, and rates of hospitalization
and work absenteeism. This analysis of the
first-year survey examines factors predictive
of glycemic control.
RESEARCH DESIGN AND
METHODS— There are five waves in
this 5-year study, each consisting of a
2-week cross-sectional and a 9-month
longitudinal survey. A 3-month interval
separates the end of the longitudinal sur-
vey and the start of the next wave. Study
design and reporting format are in accor-
dance with the recommended STROBE
(Strengthening the Reporting of Observa-
tional Studies in Epidemiology) guide-
lines (7).
During the first wave, 18 countries
recruited participants between 5 May and
28 November 2005. These were Korea,
China, Indonesia, India, Hong Kong, Tai-
wan, Malaysia, and Thailand from Asia
(n  5,888); Romania, Bulgaria, Turkey,
Tunisia, and Bosnia from Eastern Europe
(n  3,519); Argentina, Ecuador, Vene-
zuela, and Colombia from Latin America
(n 2,116); and Tunisia from Africa (n
276). Physicians enrolled the first five
type 1 diabetic and first 10 type 2 diabetic
patients aged 18 years who attended
their clinics over a 2-week period. Exclu-
sion criteria included active participation
in a clinical study or recent short-term
insulin treatment. Diabetes was defined
by the 2002 World Health Organization
criteria (8).
Data collection and outcome
measures
Data were collected on case report forms
for demographic and socioeconomic pro-
file, medical history, medications, glyce-
mic control, blood pressure and lipid
status, self-care, access to patient educa-
tion, mode of follow-up, work absentee-
ism, and hospitalization. Outcome
measures included attainment of treat-
ment goals defined as A1C 7%, blood
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pressure 130/80 mmHg, and LDL cho-
lesterol 100 mg/dl (8).
Selection of physicians and sample
size estimation
A main objective of the IDMPS is to doc-
ument the pattern of insulin usage. Thus,
endocrinologists, diabetologists, and gen-
eral practitioners with experience in initi-
ation and titration of insulin therapy were
invited to participate. The number of par-
ticipating physicians in each country was
calculated according to estimated per-
centages of insulin-treated type 2 diabetic
patients in the country. A total of 937
physicians participated, with the highest
enrollment in India (1,825 patients, 183
physicians) and the lowest enrollment in
Tunisia (361 patients, 37 physicians).
Study implementation
A steering committee advised the project
team on study design and registry struc-
ture, monitored study progress, reviewed
and validated all study-related docu-
ments, and proposed and approved deci-
sions on protocol amendments, analyses,
and publications. The study was coordi-
nated by sanofi-aventis Intercontinental. In
each country, the study was championed by
a leading diabetologist who compiled and
endorsed the list of investigators. The latter
were assisted by local sanofi-aventis staff in
collecting relevant information including
clinical and laboratory parameters. Ethics
approval was obtained from institutional
boards of each country. All participants pro-
vided written informed consent.
Statistical analysis
All data were transferred from study cen-
ters to Mapi-Naxis, France, for quality
control and analysis using SAS (version
8.02; SAS Institute, Cary, NC). Descrip-
tive analysis, ANOVA, 2 test, and Fish-
er’s exact test were used as appropriate.
Univariate and logistic regression analy-
ses were performed to identify predictive
factors for A1C 7%. Age, duration of
disease, and number of oral glucose-
lowering drugs (OGLDs) were considered
continuous variables. Due to regional het-
erogeneity, a logistic regression model per
region was performed entering factors
significant at the 10% level from the uni-
variate analysis. Odds ratios (ORs) with
95% CIs were estimated for each signifi-
cant predictor. A backward selection pro-
cedure identified predictive factors that
were significant at the 5% level. Relevant
interactions (age  time since diagnosis,
age microvascular complications, age
macrovascular complications, time since di-
agnosis  microvascular complications,
time since diagnosismacrovascular com-
plications, BMI  microvascular compli-
ca t ions , BMI  macrovascu l a r
complications, and self-monitoring of
blood glucose [SMBG] self-adjustment
of insulin) were tested, and those signifi-
cant at the 10% level were added to the
final model. A P value0.05 (two-tailed)
was considered significant. Because of the
low number of patients recruited in Tuni-
sia, the data from this country were not
included in the analysis.
RESULTS
Type 1 diabetes
Of the 1,898 type 1 diabetic patients re-
cruited by 937 physicians (Eastern Eu-
rope n  914, Asia n  512, Latin
America n  404, and Africa n  68),
20% reported diabetes-related hospital-
ization or work absenteeism in the last 6
months, 22% never had A1C measured,
and 10–30% were not screened for com-
plications in the last 24 months. Eastern
Europe had the lowest proportion of
screened patients. Clinical profiles were
similar in all three regions (50% female,
mean age 36 years, mean disease duration
11.5 years), with the lowest BMI in Asia
(Table 1).
Attainment of targets, treatment,
and self care
Among patients with available A1C, 25%
had a value 7 and 45% had attained
blood pressure and LDL cholesterol goals.
In patients with all three measurements
(n  696), 7.5% reached all three goals.
Over 70% of patients performed SMBG,
with the lowest percentage in Asia (Table
1). Approximately 80% had health cover-
age and access to diabetes educators,
whereas 16% belonged to a diabetes asso-
ciation. When stratified by SMBG and ac-
cess to diabetes educators, 29% of
patients with both factors reached the
A1C goal, compared with 21% with
SMBG only, 14% with education only,
and 8% with neither (P  0.001).
The most popular insulin regimens
were basal plus bolus in Latin America
and Eastern Europe and a premix regimen
in Asia. The mean insulin dose ranged
from 0.5 to 0.8 IU/kg, with the highest
dose used in the basal plus bolus regimen.
Irrespective of treatment regimens or in-
sulin dose, 20–30% reached the A1C goal
(data not shown).
Physicians’ perceptions and risk
factor control
Physicians were to tick yes/no checkboxes
for three questions: “Is the patient at tar-
get for glycemic control?,” “Is the patient
suffering from hypertension?,” and “Is the
patient suffering from dyslipidemia?” For
glycemic control, they answered “yes” for
717 (38%) patients, although 25% did
not have an A1C value. For 483 patients
without A1C, 38% were considered to be
at target. For patients with A1C 7%,
21% were considered to be at target, and
for those with fasting blood glucose100
mg/dl, 33% were considered to be at tar-
get. Similarly, 46% of patients untreated
for hypertension had a blood pressure
130/80 mmHg, and 40% untreated for
dyslipidemia had a LDL cholesterol level
100 mg/dl.
Predictors for glycemic control
There were few differences between pa-
tients with A1C7% and7% (Table 2).
Only SMBG was associated with two- to
threefold increased odds of reaching the
A1C goal in all three regions. Short dis-
ease duration and training by diabetes ed-
ucators were predictors of glycemic
control in Latin America (Fig. 1).
Type 2 diabetes
Of 9,901 type 2 diabetic patients re-
cruited by 937 physicians (Eastern Eu-
rope n  2,605, Asia n  5,376, Latin
America n 1,712, and Africa n 208),
10% reported diabetes-associated hospi-
talization or absenteeism from work in
the last 6 months, 33% did not have
health coverage, 36% never had A1C
measured, and 11–36% were not
screened for complications in the last 2
years. There was marked regional hetero-
geneity for performance indexes, but for
all three regions 20–40% of patients were
at target for A1C, blood pressure, or lip-
ids. In patients with all three risk factors
measured (n  3,896), 3.6% attained all
three targets. Clinical profiles were simi-
lar in the three regions (mean age 58 years
and mean disease duration 8 years), with
the lowest BMI and waist circumferences
in Asia (Table 1).
Attainment of targets, treatment,
and self-care
Insulin doses and regimens were similar
in all three regions (data not shown).
Overall, 3% of patients were treated with
diet and exercise alone, 66% with OGLDs
alone, and 31% with insulin, with or
without OGLDs (details by country avail-
IDMPS and glycemic control
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able in the online appendix at http://dx.
doi.org/10.2337/dc08-0435). Patients
treated with insulin only had mean SD
insulin doses ranging from 0.70  0.35
IU/kg in those using basal plus prandial
insulin to 0.45 0.21 IU/kg in those us-
ing basal insulin alone. Patients treated
with OGLDs plus insulin had mean doses
of 0.68 0.29 IU/kg (basal plus prandial)
and 0.35  0.20 IU/kg (basal alone). Ir-
respective of region or insulin regimen,
18–35% had A1C 7%. Overall, 42%
never received diabetes education, 32%
performed SMBG, and 8% belonged to a
diabetes association.
Physician perception versus reality
Of patients considered by physicians to
be at goal, 34% did not have an A1C value
available. Of patients with A1C 7%,
27% were considered to be at target, and
of those whose fasting blood glucose was
100 mg/dl, 41% were considered to be
at target. Among insulin-treated patients,
22% with A1C 7% were considered to
be at target. Among patients untreated for
hypertension or dyslipidemia, 63% had a
blood pressure130/80 mmHg and 35%
had LDL cholesterol 100 mg/dl.
Predictors for glycemic control
In all three regions, short disease duration
was a predictor for A1C 7%. Region-
specific predictors were lack of microvas-
cular complications and old age in Latin
America and Asia; training by a diabetes
educator, SMBG in patients who self-
adjusted insulin dosages, and lack of ma-
crovascular complications in Eastern
Europe; BMI 30 kg/m2 and self-
adjustment of insulin dosages in Asia; and
management by specialists and having
health insurance coverage in Latin Amer-
ica (Table 2, Fig. 2). In patients treated
with OGLDs only, use of fewer OGLDs
was a predictor for reaching target in all
three regions (Fig. 3).
CONCLUSIONS— This multina-
tional survey confirms the chasm between
guidelines and practice in Asia, Eastern
Europe, and Latin America. Based on case
records, 10–40% of patients were not
screened for risk factors or complications
in the last 24 months. Only 20–30% of
patients were at the A1C goal, whereas
7.5% of type 1 and 3.6% of type 2 diabetic
patients attained three treatment goals.
Furthermore, 20% of type 1 and 10% of
type 2 diabetic patients reported hospital-
ization or work absenteeism in the past 6
months. Such suboptimal performance
indexes call for closer surveillance to im-
prove control.
Greater education needed
Whether managed by specialists or gen-
eral practitioners, patients had similar
patterns of care and levels of control. In
both types of diabetes, there was signifi-
cant mismatch between patient risk factor
control and physician perception. Many
physicians noted adequate glycemic con-
trol despite nonavailability of A1C mea-
surements, whereas others overestimated
the proportions of patients at goal. This
agrees with other reports of delayed esca-
lation in therapy (clinical inertia) and
clinical assessments not translated into
actions to improve control (9). Our find-
ings are also consistent with those re-
ported in Europe and the U.S., although
reports from these regions show a slow
trend of improvement in practice
(10 –12).
Predictors of glycemic control
In both diabetes types, although body
weight–adjusted insulin doses were
within recommended guidelines, neither
doses nor regimens predicted glycemic
control. SMBG was the only predictor for
glycemic control in all three regions for
type 1 diabetes. In Latin America, short
disease duration and training by diabetes
educators were also predictors: patients
who had diabetes education and per-
formed SMBG were fourfold more likely
to be at target than those with neither (29
vs. 7%).
In type 2 diabetes, despite regional
heterogeneity, short disease duration and
use of few OGLDs were predictive factors
in all three regions. In Asia and South
America, absence of microvascular com-
plications was an additional predictor.
These findings suggest that early diagno-
sis and prompt initiation of insulin ther-
apy in patients treated with multiple
OGLDs may increase the likelihood of at-
taining glycemic targets, although defini-
tive studies are required. In Asia and
South America, old age was a predictor,
which agrees with data from the U.S. Di-
abetes Prevention Program, showing life-
style modification was more effective in
elderly than young people (13), who may
be less compliant because of competing
priorities (14). In Asia, lack of obesity and
self-adjustment of insulin dosages were
predictors, emphasizing the double hit
of obesity and -cell insufficiency in
Asian populations (15). Other region-
specific factors relevant to self-careT
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(e.g., SMBG and self-adjustment of in-
sulin) and health care systems (e.g.,
health insurance coverage and access to
specialists and diabetes educators)
highlight the multiple challenges in op-
timizing diabetes care.
Strengths and weaknesses of our
study
Whereas standardized methods used in
the IDMPS allowed regional comparisons
of diabetes practices, there are potential
limitations including nonstandardized
laboratory assays and assessments of
complications. Selection of physicians ex-
perienced with insulin may introduce
bias by overrepresenting patients with ad-
vanced diseases or complex regimens.
However, the majority of patients were
treated with OGLDs, and our analyses
show that factors pertaining to the health
care system, including access to educa-
tors, laboratory tests, and medications,
are important barriers to achieving glyce-
mic control. Inferring from these find-
ings, we speculate that physicians with
less system support and experience may
face even greater challenges in managing
these patients with multiple needs. De-
spite its cross-sectional nature, our data
strongly suggest that prompt diagnosis,
early intervention, and self-management
are important determinants for glycemic
control.
In conclusion, apart from contribut-
ing to the global landscape of diabetes
practice, our data enable us to track per-
formance indexes over time and gener-
ate a hypothesis to explain suboptimal
diabetes care. Our findings have quan-
tified factors pertinent to patients, care
providers, and the health care system,
all of which impact on the quality of
diabetes care. There is an urgent need
for the public, policy makers, and care
Figure 2—Predictive factors for attaining A1C 7% in patients with type 2 diabetes, divided by regions.
Figure 1—Predictive factors for attaining A1C 7% in patients with type 1 diabetes, divided by regions.
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providers to develop a strategy encom-
passing education, audits, mandates,
and incentives to make multidisci-
plinary care and self-management more
accessible, sustainable, and affordable
(16).
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